Literature DB >> 7690321

The novel subset of CD14+/CD16+ blood monocytes exhibits features of tissue macrophages.

H W Ziegler-Heitbrock1, G Fingerle, M Ströbel, W Schraut, F Stelter, C Schütt, B Passlick, A Pforte.   

Abstract

The CD14+/CD16+ cells account for about 10% of all blood monocytes. They are characterized by a low level expression of the CD14 molecule and a high level expression of the CD16 (Fc gamma R III) molecule. Polymerase chain reaction analysis of mRNA prevalence in CD14+/CD16+ cells (compared to the regular CD14++ blood monocytes) demonstrates low levels of CD14 transcripts and high levels of CD16 transcripts, suggestive of a transcriptional control for both of these proteins. Analysis of additional cell surface molecules in three-color immunofluorescence reveals that CD14+/CD16+ cells express the Fc gamma R II in all, and Fc gamma R I and ICAM-1 in some donors. Furthermore, class II antigens are expressed at fourfold higher levels, while both, CD11b and CD33 cell surface proteins, are decreased by a factor of two. Transcript levels were reduced in CD14+/CD16+ cells for all three cell surface molecules. Since these phenotypic markers of the CD14+/CD16+ blood monocytes are reminiscent of tissue macrophages, we performed a comparative analysis with alveolar macrophages (AM). These cells are similar to the CD14+/CD16+ monocytes in that they show low levels of CD14 and strong expression of CD16. Furthermore, similar to the CD14+/CD16+ cells, the AM also exhibit higher levels of class II and lower levels of CD11b and CD33 when compared to the regular CD14++ blood monocytes. In vitro induction of maturation of blood monocytes by 5 day culture of peripheral blood mononuclear cells in 10% human serum will result in decreased CD14 and increased CD16 cell surface expression on the monocyte derived macrophages. At the same time, these cells acquire increased levels of class II and decreased levels of CD11b and CD33. Taken together, these data show that CD14+/CD16+ monocytes, while still in circulation, have acquired features in common with mature tissue macrophages.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7690321     DOI: 10.1002/eji.1830230902

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  104 in total

1.  Surface phenotype analysis of CD16+ monocytes from leukapheresis collections for peripheral blood progenitors.

Authors:  M Tanaka; J Honda; Y Imamura; K Shiraishi; K Tanaka; K Oizumi
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

2.  CD14+CD16+ monocyte subpopulation in Kawasaki disease.

Authors:  K Katayama; T Matsubara; M Fujiwara; M Koga; S Furukawa
Journal:  Clin Exp Immunol       Date:  2000-09       Impact factor: 4.330

3.  Investigating the role of proinflammatory CD16+ monocytes in the pathogenesis of inflammatory bowel disease.

Authors:  S Koch; T Kucharzik; J Heidemann; A Nusrat; A Luegering
Journal:  Clin Exp Immunol       Date:  2010-05-07       Impact factor: 4.330

Review 4.  The multiple roles of monocyte subsets in steady state and inflammation.

Authors:  Clinton S Robbins; Filip K Swirski
Journal:  Cell Mol Life Sci       Date:  2010-05-01       Impact factor: 9.261

5.  Magnetic resonance spectroscopy reveals that activated monocytes contribute to neuronal injury in SIV neuroAIDS.

Authors:  Kenneth Williams; Susan Westmoreland; Jane Greco; Eva Ratai; Margaret Lentz; Woong-Ki Kim; Robert A Fuller; John P Kim; Patrick Autissier; Prahbat K Sehgal; Raymond F Schinazi; Norbert Bischofberger; Michael Piatak; Jeffrey D Lifson; Eliezer Masliah; R Gilberto González
Journal:  J Clin Invest       Date:  2005-08-18       Impact factor: 14.808

6.  Systemic immune system alterations in early stages of Alzheimer's disease.

Authors:  Rongzhen Zhang; Robert G Miller; Catherine Madison; Xia Jin; Ronald Honrada; Will Harris; Jonathan Katz; Dallas A Forshew; Michael S McGrath
Journal:  J Neuroimmunol       Date:  2013-02-04       Impact factor: 3.478

7.  Untreated stage IV melanoma patients exhibit abnormal monocyte phenotypes and decreased functional capacity.

Authors:  Rahul Chavan; Daniela Salvador; Michael P Gustafson; Allan B Dietz; Wendy Nevala; Svetomir N Markovic
Journal:  Cancer Immunol Res       Date:  2013-11-18       Impact factor: 11.151

8.  Glucocorticoid treatment at moderate doses of SIVmac251-infected rhesus macaques decreases the frequency of circulating CD14+CD16++ monocytes but does not alter the tissue virus reservoir.

Authors:  Marcin Moniuszko; Namal P M Liyanage; Melvin N Doster; Robyn Washington Parks; Kamil Grubczak; Danuta Lipinska; Katherine McKinnon; Charles Brown; Vanessa Hirsch; Monica Vaccari; Shari Gordon; Poonam Pegu; Claudio Fenizia; Robert Flisiak; Anna Grzeszczuk; Milena Dabrowska; Marjorie Robert-Guroff; Guido Silvestri; Mario Stevenson; Joseph McCune; Genoveffa Franchini
Journal:  AIDS Res Hum Retroviruses       Date:  2015-01       Impact factor: 2.205

9.  CD14++CD16+ Monocytes Are Enriched by Glucocorticoid Treatment and Are Functionally Attenuated in Driving Effector T Cell Responses.

Authors:  Baoying Liu; Ashwin Dhanda; Sima Hirani; Emily L Williams; H Nida Sen; Fernando Martinez Estrada; Diamond Ling; Ian Thompson; Megan Casady; Zhiyu Li; Han Si; William Tucker; Lai Wei; Shayma Jawad; Amol Sura; Jennifer Dailey; Susan Hannes; Ping Chen; Jason L Chien; Siamon Gordon; Richard W J Lee; Robert B Nussenblatt
Journal:  J Immunol       Date:  2015-04-24       Impact factor: 5.422

Review 10.  Drug induced increases in CNS dopamine alter monocyte, macrophage and T cell functions: implications for HAND.

Authors:  Peter J Gaskill; Tina M Calderon; Jacqueline S Coley; Joan W Berman
Journal:  J Neuroimmune Pharmacol       Date:  2013-03-01       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.